These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 18617622)

  • 1. Modulation of osteoclastogenesis by fatty acids.
    Cornish J; MacGibbon A; Lin JM; Watson M; Callon KE; Tong PC; Dunford JE; van der Does Y; Williams GA; Grey AB; Naot D; Reid IR
    Endocrinology; 2008 Nov; 149(11):5688-95. PubMed ID: 18617622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
    Kim HN; Ha H; Lee JH; Jung K; Yang D; Woo KM; Lee ZH
    Eur J Pharmacol; 2009 Nov; 623(1-3):22-9. PubMed ID: 19766111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
    Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
    Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biselyngbyaside, isolated from marine cyanobacteria, inhibits osteoclastogenesis and induces apoptosis in mature osteoclasts.
    Yonezawa T; Mase N; Sasaki H; Teruya T; Hasegawa S; Cha BY; Yagasaki K; Suenaga K; Nagai K; Woo JT
    J Cell Biochem; 2012 Feb; 113(2):440-8. PubMed ID: 21678460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble glucocorticoid-induced tumor necrosis factor receptor stimulates osteoclastogenesis by down-regulation of osteoprotegerin in bone marrow stromal cells.
    Shin HH; Kim SJ; Kang SY; Lee DS; Choi HS
    Bone; 2006 Oct; 39(4):716-23. PubMed ID: 16750437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caffeine enhances osteoclast differentiation from bone marrow hematopoietic cells and reduces bone mineral density in growing rats.
    Liu SH; Chen C; Yang RS; Yen YP; Yang YT; Tsai C
    J Orthop Res; 2011 Jun; 29(6):954-60. PubMed ID: 21284030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harmine, a β-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo.
    Yonezawa T; Hasegawa S; Asai M; Ninomiya T; Sasaki T; Cha BY; Teruya T; Ozawa H; Yagasaki K; Nagai K; Woo JT
    Eur J Pharmacol; 2011 Jan; 650(2-3):511-8. PubMed ID: 21047508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicarpin inhibits osteoclastogenesis and has nonestrogenic bone conserving effect in ovariectomized mice.
    Tyagi AM; Gautam AK; Kumar A; Srivastava K; Bhargavan B; Trivedi R; Saravanan S; Yadav DK; Singh N; Pollet C; Brazier M; Mentaverri R; Maurya R; Chattopadhyay N; Goel A; Singh D
    Mol Cell Endocrinol; 2010 Aug; 325(1-2):101-9. PubMed ID: 20570709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The natural flavonoid galangin inhibits osteoclastic bone destruction and osteoclastogenesis by suppressing NF-κB in collagen-induced arthritis and bone marrow-derived macrophages.
    Huh JE; Jung IT; Choi J; Baek YH; Lee JD; Park DS; Choi DY
    Eur J Pharmacol; 2013 Jan; 698(1-3):57-66. PubMed ID: 22985747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
    Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
    Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineral trioxide aggregate solution inhibits osteoclast differentiation through the maintenance of osteoprotegerin expression in osteoblasts.
    Hashiguchi D; Fukushima H; Nakamura M; Morikawa K; Yasuda H; Udagawa N; Maki K; Jimi E
    J Biomed Mater Res A; 2011 Feb; 96(2):358-64. PubMed ID: 21171155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
    Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
    J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms.
    O'Sullivan S; Naot D; Callon K; Porteous F; Horne A; Wattie D; Watson M; Cornish J; Browett P; Grey A
    J Bone Miner Res; 2007 Nov; 22(11):1679-89. PubMed ID: 17663639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.
    Lee SK; Lorenzo JA
    Endocrinology; 1999 Aug; 140(8):3552-61. PubMed ID: 10433211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
    Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels.
    Kondo T; Kitazawa R; Yamaguchi A; Kitazawa S
    J Cell Biochem; 2008 Jan; 103(1):335-45. PubMed ID: 17516544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro.
    Saleh H; Eeles D; Hodge JM; Nicholson GC; Gu R; Pompolo S; Gillespie MT; Quinn JM
    Endocrinology; 2011 May; 152(5):1911-22. PubMed ID: 21363931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of signal transducer and activator of transcription 3.
    Duplomb L; Baud'huin M; Charrier C; Berreur M; Trichet V; Blanchard F; Heymann D
    Endocrinology; 2008 Jul; 149(7):3688-97. PubMed ID: 18403479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.